Economic impact of MMR vaccine hesitancy in the US

Economic impact of MMR vaccine hesitancy in the US PharmacoEconomics & Outcomes News 784, p15 - 12 Aug 2017 Economic impact of MMR vaccine hesitancy in the US Minor reductions in measles, mumps and rubella (MMR) vaccine coverage in US children due to vaccine hesitancy would be associated with significant public health and economic consequences, according to a study published in JAMA Pediatrics. The authors investigated the potential economic implications and effects on public health of vaccine hesitancy, the delay or refusal of vaccination due to personal beliefs. Publicly available data from the US Centers for Disease Control and Prevention was used to simulate vaccination coverage for the MMR vaccine in US children aged 2 to 11 years. A stochastic model modified for transmission of infectious diseases was used to estimate outbreak size relative to vaccine coverage, with model prediction validation undertaken against an independent data set from England and Wales. Using available literature, an estimated cost of $US20 000 per case of measles was applied from a public sector perspective using US 2016 dollar values. The study found that a 5% decrease in MMR vaccine coverage would be associated with a 3-fold increase in measles cases in US children aged 2–11 years, with additional economic costs to the public sector of $2.1 million. The authors estimated that eliminating nonmedical exemptions could potentially increase the national MMR vaccine coverage from the baseline prevalence of 93% to 95%, which would result in a 20% reduction in annual measles cases. Although some variation existed around these estimates due to the stochastic elements of measles importation, the correlation was robust between decreasing MMR vaccine coverage and increasing numbers of measles cases. The authors concluded that the results "directly confront the notion that measles is no longer a threat in the United States" and "should play a key role in any policies adapted by state or national governments that relate to childhood vaccination". Lo NC, et al. Public Health and Economic Consequences of Vaccine Hesitancy for Measles in the United States. JAMA Pediatrics : 24 Jul 2017. Available from: URL: 803261499 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

Economic impact of MMR vaccine hesitancy in the US

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial